Back to News
Market Impact: 0.4
LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review and Closes Acquisition from Tanabe Pharma
Source: Business Wire
Healthcare & BiotechM&A & RestructuringRegulation & Legislation
LEO Pharma said the FDA accepted its New Drug Application for dersimelagon and granted Priority Review, accelerating the regulatory review timeline for the treatment. The company also completed its acquisition from Tanabe Pharma, adding a strategic corporate-development milestone alongside the potential product catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- California’s Bay Area debates data centres ahead of US midterm elections
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Going hungry’: Garment workers in Bangladesh say wages barely cover needs